Finch Therapeutics

Finch Therapeutics

  • Founded: 2014
  • Location: Somerville, MA
  • Employee range: 1 - 10
  • Funding: $127.5M IPO Mar 2021; $90M D Sep 2020; $53M Aug 2019; $30M Mar 2018
  • Investors: OCV Partners, Susquehanna International¬†Group, Trans-Pacific Technology Fund, Avenir Growth Capital, Morgan Noble, Shumway Capital, Willett Advisors

job board

Short description:

Microbiological Therapy

Drug notes:

Contact us to add description:

Long description:

Finch Therapeutics is establishing a portfolio of microbiome therapeutics to treat patients with serious and unmet conditions. The microbiome consists of trillions of microbes that live symbiotically on and within humans. Disruption of the microbe composition can increase susceptibility to immune disorders, infections, neurological conditions and cancer. Finch is designing microbiome assets using insights from human microbiota transplantation studies that spans dozens of different conditions. With this information, Finch has established an extensive, multi-layered patent protection for multiple microbiome product strategies including donor-derived and donor-independent which they can now use to generate therapies.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy